Edition:
United States

Supernus Pharmaceuticals Inc (SUPN.OQ)

SUPN.OQ on NASDAQ Stock Exchange Global Market

39.05USD
22 Nov 2017
Change (% chg)

-- (--)
Prev Close
$39.05
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
188,891
52-wk High
$50.03
52-wk Low
$20.60

Chart for

About

Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In... (more)

Overall

Beta: 1.25
Market Cap(Mil.): $2,001.79
Shares Outstanding(Mil.): 51.26
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.51 15.54
EPS (TTM): -- -- --
ROI: -- 15.16 11.80
ROE: -- 16.57 15.75

BRIEF-Supernus announces third quarter 2017 financial results

* Q3 earnings per share view $0.27 -- Thomson Reuters I/B/E/S

Nov 06 2017

BRIEF-Supernus defeats second generic challenger to Oxtellar XR

* Supernus - Court ruled TWi Pharmaceuticals, unit infringed U.S. Patents by submitting to FDA, ANDA to market generic version of Oxtellar XR Source text for Eikon: Further company coverage:

Aug 15 2017

BRIEF-Supernus Q2 earnings per share $0.32

* Supernus announces record second quarter 2017 financial results

Aug 02 2017

BRIEF-Supernus says Shire receives FDA approval for Mydayis for ADHD

* Supernus announces that its partner Shire receives FDA approval for Mydayis™ for ADHD

Jun 21 2017

Competitors

  Price Chg
Abbott Laboratories (ABT.N) $56.13 +0.33
AstraZeneca plc (AZN.L) 4,980.50 -19.00
Eli Lilly and Co (LLY.N) $84.03 +0.35
Shire PLC (SHP.L) 3,735.00 --
Shire PLC (3159084.L) -- --
Smiths Group plc (SMIN.L) 1,507.00 --

Earnings vs. Estimates